Bryan Clickener’s Post

🔍 Have you ever wondered why GLP-1 drugs for weight management may stop working over time? Dr. Fatima Cody Stanford and Dr. Anne L. Peters shed light on this phenomenon, emphasizing the importance of setting realistic expectations in the journey of weight loss. 📌 Everyone has a unique weight 'set point', and weight loss interventions, including GLP-1 drugs, may eventually reach a plateau, raising the need for a multifacted approach to support patients through their journey. Share your thoughts and experiences below! 💬 #ObesityManagement #ChronicDiseaseCare #HealthJourney #ObesityMatters https://ow.ly/JnLA50QsU7W

1 in 8 US adults now say they have used GLP-1 drugs, but what many herald as a "miracle drug" for weight loss is now increasingly associated with a list of potential negative side effects—one of the latest being muscle loss. While data related to this topic continues to surface, our medical team weighs in on what we do know about GLP-1s and muscle loss, why it matters, who is most at risk, and what employers and payers can do to mitigate the potential for poor outcomes and higher costs while also meeting the demands of their members. Read article: https://lnkd.in/gTpNv9_j #glp1 #muscleloss #msk

Sharpen your mind, not dull it! ❌ Avoid these habits that can harm your brain health. #BrainHealth #HealthyHabits #Pharma #Pharmacy #Healthcare #LifeSciences #MedTech #DrugDiscovery #ClinicalTrials #PatientCare #HealthcareInnovation #FutureOfPharma #India #Tanzania #Medix #Medixmovement

What's a good way to keep up with the big pharmacy news in a few minutes each quarter? --- Every quarter or so, Milliman releases a pharmacy brief (in the comments) that summarizes some of the big pharmacy-related updates from the past few months. The newest brief includes some updates such as: - The newest benefits of GLP-1s (heart disease, sleep apnea) and how employers can modernize care for #obesity - Big #biosimilars that were approved (e.g. biosimilars to Humira, Stelara, and Eylea) and biosimilar #policy reform - The first MASH drug approval--Rezdiffra - The proposal to make cannabis a schedule 3 controlled substance (instead of schedule 1) --- You only need about 5 minutes to catch up with the big #pharmacy news from the last few months if you get it from this publication. If you're pharmacy-adjacent or just pharmacy-curious, it's a great way to keep up with the constant shifts that happen. Brian A. Rebekah Bayram Marc Guieb

🌖 Nighttime Cannabis Use for insomnia patients: A Step Forward in Safe, Effective Treatment 🌖 Exciting news from recent Australian clinical trial shows that cannabis oil used at night poses no risk of next-day impairment. At THERAKANN PHARMACEUTICALS we believe in creating products that support both wellness and daily performance. This study is a testament to the potential of cannabis as a reliable, safe solution for enhancing sleep and overall well-being. 🔗 to article: https://lnkd.in/dUPmRYXP Discover how we are leading the charge in integrating ancient wisdom with cutting-edge science to redefine the cannabis wellness experience at www.therakann.com #medicalcannabis #insomnia #clinicaltrial #research #cannabis

Exciting news! MDLinx covered an article on the new risks associated with popular weight loss drugs like Ozempic and Wegovy. I had the privilege to share my insights on the effects of the up-and-coming weight loss medications within the industry. As you can imagine, as a weight loss doctor, Weight loss medication, is something I get inquiries on all the time. If you've been hearing about weight loss medication and have been curious to learn more, please take a few minutes of your time to read this article. I encourage you to be well-versed in the advantages and disadvantages of these popular weight loss drugs. https://lnkd.in/eGkjG8bn #Weightloss #GLP1Drugs #Healthcareresearch

As the demand for GLP-1 receptor agonist drugs continues to rise, plan sponsors face the challenge of ensuring their optimal and safe use within their health plans. The key to success lies in implementing effective educational programs and decision-support tools. By providing plan members with the knowledge and resources they need to make informed decisions about GLP-1 use, sponsors can: ✅ Promote the responsible use of these medications ✅ Maximize the benefits for eligible members ✅ Minimize potential risks and adverse events By investing in these initiatives, plan sponsors can ensure that GLP-1s are used in a manner that optimizes outcomes, manages costs, and prioritizes member health and well-being. #GLP1Optimization #SponsoredHealthPlans #EducationalPrograms #Healthcare

Prepared for the Future of Weight Management Drugs? GLPs and weight management drugs should never be prescribed in isolation. Comprehensive approaches are essential to ensure better patient outcomes and empower individuals for long-term health success. That's why Zaya is thrilled about how companies, #privatepractices, and #dietitians embrace technology to transform healthcare. The Advisory Board recently shared expert insights on "5 catalysts impacting the future of weight management drugs", and speaks to how stakeholders can prepare for this evolving ecosystem: https://lnkd.in/gVWvdVsx Right now, tech companies are reshaping healthcare by establishing marketplaces and provider networks that facilitate access to registered dietitians (RDNs). This means patients now have seamless access to RDNs tailored to their unique needs, while dietitians themselves can experience unprecedented levels of empowerment and support. Through strategic partnerships with #healthtech companies like Zaya, dietitians—and other specialists—can expand their private practices to serve insured patients and elevate business outcomes. #Tech has revolutionized processes for getting in-network, checking patient eligibility, submitting claims, ensuring timely payouts, and even appealing denials, and it doesn't stop there. Because of these innovations, providers can focus on what they do best: giving people the tools to enjoy healthy lives.

“Excited to share my journey with #Etorax90, a powerful pain-relief medication from #DARMAANPHARMA. This medicine, containing Etoricoxib, has been instrumental in managing moderate pain and swelling associated with arthritis and gout. It’s been a true relief, reducing pain, redness, and swelling, and significantly improving my quality of life. Remember, it’s important to take this medication as advised by your healthcare professional. #MyHealthcareJourney #PharmaInnovation #ResponsibleUseOfMedications #HealthFirst #HealingPower #TrustInDarmaan #DarmaanHeals #Pharmacy #DrugDevelopment #Medicine #Pharmacology #HealingPower #DarmaanPharma #HealthcareInnovation #PharmaceuticalAdvancements”

“Introducing #Etorax90 from #DARMAANPHARMA, a potent pain-relieving medicine. Etorax 90, containing Etoricoxib, is used for relieving moderate pain and swelling associated with various forms of arthritis and gout. It effectively alleviates pain, redness, and swelling, improving the quality of life for those suffering from these conditions. Always remember to take this medication as advised by your healthcare professional and use responsibly. #Healthcare #Pharma #PainRelief #HealthFirst #HealingPower #TrustInDarmaan #DarmaanHeals #Pharmacy #DrugDevelopment #Medicine #Pharmacology #HealingPower #DarmaanPharma #HealthcareInnovation #PharmaceuticalAdvancements”